Novel approach to demonstrate high efficacy of μ opioids in the rat vas deferens: A simple model of predictive value

Brain Research Bulletin

Volumn 81, Issue 1, 2010, Pages 178-184

  Riba, Pál ^a   Friedmann, Tamás ^a   Király, Kornél P ^a   Al Khrasani, Mahmoud ^a   Sobor, Melinda ^a,b   Asim, Muhammad F ^c   Spetea, Mariana ^c   Schmidhammer, Helmut ^c   Furst, Susanna ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Orszagos Gyogyszereszeti Intezet   (Hungary)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Opioid receptors; Antinociception; Efficacy; Morphinans; Mouse vas deferens; Rat vas deferens

Indexed keywords

14 METHOXYMETOPON; 14 METHYLOXYMORPHONE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALTREXONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MUSCLE TWITCH; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; VAS DEFERENS;

ANALGESICS, OPIOID; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; MALE; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; MORPHINE; MORPHINE DERIVATIVES; NALTREXONE; OXYMORPHONE; PAIN; RATS; RATS, WISTAR; RECEPTORS, OPIOID, MU; VAS DEFERENS;

EID: 71349083802     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.09.011     Document Type: Article

References (37)

1. Al-Khrasani M., Spetea M., Friedmann T., Riba P., Kiraly K., Schmidhammer H., and Furst S. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens. Brain Res. Bull. 74 (2007) 369-375
2. Avdeef A. pH-metric log P. II. Refinement of partition coefficients and ionization constants of multiprotic substances. J. Pharm. Sci. 82 (1993) 183-190
3. Bileviciute-Ljungar I., Spetea M., Guo Y., Schutz J., Windisch P., and Schmidhammer H. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]ace tic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation. J. Pharmacol. Exp. Ther. 317 (2006) 220-227
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Contet C., Matifas A., and Kieffer B.L. No evidence for G-protein-coupled epsilon receptor in the brain of triple opioid receptor knockout mouse. Eur. J. Pharmacol. 492 (2004) 131-136
6. Freye E., Schmidhammer H., and Latasch L. 14-Methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog. Anesth. Analg. 90 (2000) 1359-1364
7. Furst Z., Buzas B., Friedmann T., Schmidhammer H., and Borsodi A. Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series. Eur. J. Pharmacol. 236 (1993) 209-215
8. Furst S., Riba P., Friedmann T., Timar J., Al-Khrasani M., Obara I., Makuch W., Spetea M., Schutz J., Przewlocki R., Przewlocka B., and Schmidhammer H. Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J. Pharmacol. Exp. Ther. 312 (2005) 609-618
9. Greiner E., Spetea M., Krassnig R., Schullner F., Aceto M., Harris L.S., Traynor J.R., Woods J.H., Coop A., and Schmidhammer H. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships. J. Med. Chem. 46 (2003) 1758-1763
10. Hylden J.L., and Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 67 (1980) 313-316
11. Kaufman D.L., Keith Jr. D.E., Anton B., Tian J., Magendzo K., Newman D., Tran T.H., Lee D.S., Wen C., Xia Y.R., et al. Characterization of the murine mu opioid receptor gene. J. Biol. Chem. 270 (1995) 15877-15883
12. King M.A., Su W., Nielan C.L., Chang A.H., Schutz J., Schmidhammer H., and Pasternak G.W. 14-Methoxymetopon, a very potent mu-opioid receptor-selective analgesic with an unusual pharmacological profile. Eur. J. Pharmacol. 459 (2003) 203-209
13. Kiraly K.P., Riba P., D'Addario C., Di Benedetto M., Landuzzi D., Candeletti S., Romualdi P., and Furst S. Alterations in prodynorphin gene expression and dynorphin levels in different brain regions after chronic administration of 14-methoxymetopon and oxycodone-6-oxime. Brain Res. Bull. 70 (2006) 233-239
14. Kosterlitz H.W., and Watt A.J. Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. Chemother. 33 (1968) 266-276
15. Lattanzi R., Spetea M., Schullner F., Rief S.B., Krassnig R., Negri L., and Schmidhammer H. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. J. Med. Chem. 48 (2005) 3372-3378
16. Lemaire S., Magnan J., and Regoli D. Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br. J. Pharmacol. 64 (1978) 327-329
17. Litchfield Jr. J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
18. Mahurter L., Garceau C., Marino J., Schmidhammer H., Toth G., and Pasternak G.W. Separation of binding affinity and intrinsic activity of the potent mu-opioid 14-methoxymetopon. J. Pharmacol. Exp. Ther. 319 (2006) 247-253
19. Miller L., Shaw J.S., and Whiting E.M. The contribution of intrinsic activity to the action of opioids in vitro. Br. J. Pharmacol. 87 (1986) 595-601
20. Monory K., Bourin M.C., Spetea M., Tomboly C., Toth G., Matthes H.W., Kieffer B.L., Hanoune J., and Borsodi A. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2. Eur. J. Neurosci. 12 (2000) 577-584
21. Niu L., Chen T., Wang Y.Y., and Li Y.Q. Neurochemical phenotypes of endomorphin-2-containing neurons in vagal nodose neurons of the adult rat. Neurochem. Int. 55 (2009) 542-551
22. Paldy E., Bereczki E., Santha M., Wenger T., Borsodi A., Zimmer A., and Benyhe S. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem. Int. 53 (2008) 309-316
23. Paldyova E., Bereczki E., Santha M., Wenger T., Borsodi A., and Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem. Int. 52 (2008) 321-328
24. Riba P., Ben Y., Nguyen T.M., Furst S., Schiller P.W., and Lee N.M. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine. Curr. Med. Chem. 9 (2002) 31-39
25. Ronai A.Z., Al-Khrasani M., Benyhe S., Lengyel I., Kocsis L., Orosz G., Toth G., Kato E., and Tothfalusi L. Partial and full agonism in endomorphin derivatives: comparison by null and operational model. Peptides 27 (2006) 1507-1513
26. Ronai A.Z., Berzetei I.P., Bajusz S., and Szekely J.I. The in vitro pharmacology of d-Met2,Pro5-enkephalinamide. J. Pharm. Pharmacol. 33 (1981) 534-535
27. Schmidhammer H., Aeppli L., Atwell L., Fritsch F., Jacobson A.E., Nebuchla M., and Sperk G. Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones. J. Med. Chem. 27 (1984) 1575-1579
28. Schmidhammer H., Schratz A., and Mitterdorfer J. Synthesis and biological evaluation of 14-alkoxymorphinans. 8. 14-methoxymetopon, an extremely potent opioid agonist. Helv. Chim. Acta 73 (1990) 1784-1787
29. Schulz R., Wuster M., and Herz A. Pharmacological characterization of the epsilon-opiate receptor. J. Pharmacol. Exp. Ther. 216 (1981) 604-606
30. Sheehan M.J., Hayes A.G., and Tyers M.B. Lack of evidence for epsilon-opioid receptors in the rat vas deferens. Eur. J. Pharmacol. 154 (1988) 237-245
31. Smith C.F., and Rance M.J. Opiate receptors in the rat vas deferens. Life Sci. 33 Suppl. 1 (1983) 327-330
32. Spetea M., Friedmann T., Riba P., Schutz J., Wunder G., Langer T., Schmidhammer H., and Furst S. In vitro opioid activity profiles of 6-amino acid substituted derivatives of 14-O-methyloxymorphone. Eur. J. Pharmacol. 483 (2004) 301-308
33. Spetea M., Toth F., Schutz J., Otvos F., Toth G., Benyhe S., Borsodi A., and Schmidhammer H. Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur. J. Neurosci. 18 (2003) 290-295
34. Tulunay F.C., and Takemori A.E. The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J. Pharmacol. Exp. Ther. 190 (1974) 395-400
35. Uriguen L., Fernandez B., Romero E.M., De Pedro N., Delgado M.J., Guaza C., Schmidhammer H., and Viveros M.P. Effects of 14-methoxymetopon, a potent opioid agonist, on the responses to the tail electric stimulation test and plus-maze activity in male rats: neuroendocrine correlates. Brain Res. Bull. 57 (2002) 661-666
36. Wuster M., Schulz R., and Herz A. Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors. Neurosci. Lett. 15 (1979) 193-198
37. Zernig G., Saria A., Krassnig R., and Schmidhammer H. Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon. Life Sci. 66 (2000) 1871-1877